Learning Objectives

Upon completion of the activity, participants should be able to:

Analyze recent trends regarding hypothyroid management in the United State, use of statins in conjunction with IV glucocorticoids in the treatment of Graves eye disease and recent data informing management for the thyroid cancer risk spectrum
Interpret serum T3 and serum T4 levels on LT4-treated patients and current approaches to LT3 and use in treatment of hypothyroidism
Review strengths and weaknesses of using different classes of Thyroglobulin (Tg) method to monitor Differentiated Thyroid Cancer (DTC) patients amd Diagnose and manage checkpoint inhibitors-induced thyroid dysfunction
Describe how the latest therapeutic considerations are shaping the new treatment paradigm of hyperthyroidism during pregnancy
Describe FDA approved and investigational targeted therapies for thyroid cancer in the context of clinical trials

Accreditation

Target Audience

This educational initiative is intended for Endocrinologists.

Accreditation Statement

The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Endocrinology designates this enduring activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Disclosures/Conflicts of Interest

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.

Faculty Disclosures

First	MI	Last	Credentials	Position	Institution	Role	Disclosure(s)
Benjamin	J.	Gigliotti	MD	Assistant Professor of Medicine	University of Rochester	Speaker	Blueprint Medicines (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- RET+ Virtual Thyroid Discussion Forum (a 7-hour advisory board commitment), started 3/3/21, ended 3/17/21)
Alex		Tessnow	MD	Associate Professor	University of Texas Southwestern Medical Center	Speaker/Moderator	Horizon (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Spectrix Therapeutics (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)
Antonio	C.	Bianco	MD, PhD	Professor of Medicine	University of Chicago	Speaker	Abbott/AbbVie (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Allergan (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Synthonic (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)
Giuseppe		Barbesino	MD	Assistant Professor	Massachusetts General Hospital/Harvard Medical School	Speaker	Horizon Pharma (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)
Anupam		Kotwal	MD	Assistant Professor	University of Nebraska Medical Center	Speaker	Horizon Therapeutics, Inc. (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)
Maria	E.	Cabanillas	MD, FACE	Professor	The University of Texas MD Anderson Cancer Center	Speaker	Bayer (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Eisai (Self) : Research Grant (Status: Terminated --- 11/15/2019); Eli Lilly (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Exelixis (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Genentech (Self) : Research Grant (Status: Ongoing); LOXO (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing), Research Grant (Status: Ongoing); Merck (Self) : Research Grant (Status: Ongoing)
Mimi		Hu	MD	Professor	The University of Texas MD Anderson Cancer Center	Moderator	Eli Lilly (Self) : Contracted Research (Status: Ongoing)

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The American Association of Clinical presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The American Association of Clinical Endocrinology assumes no liability for the information herein.

Summary


Availability:	On-Demand
	Expires on Jul 21, 2023


Cost:	Member: $127.50 Non-Member: $212.50

Credit Offered:

5.75 CME Credits

5.75 ABIM-MOC Points